Literature DB >> 21841893

Ovarian Cancer Tests and Treatment.

Jori S Carter1, Levi S Downs.   

Abstract

Lack of symptoms in early-stageovarian cancer leads to a high mortality rate overall. Tests and therapy are discussed here, along with the symptom index.

Entities:  

Year:  2011        PMID： 21841893      PMCID： PMC3154728     

Source DB:  PubMed          Journal:  Female Patient (Parsippany)        ISSN： 0888-2398


  10 in total

1.  ACOG Committee Opinion: number 280, December 2002. The role of the generalist obstetrician-gynecologist in the early detection of ovarian cancer.

Authors: 
Journal:  Obstet Gynecol       Date:  2002-12       Impact factor: 7.661

2.  Doctor, should I get this new ovarian cancer test-OVA1?

Authors:  Carolyn Y Muller
Journal:  Obstet Gynecol       Date:  2010-08       Impact factor: 7.661

3.  A recipe for proteomics diagnostic test development: the OVA1 test, from biomarker discovery to FDA clearance.

Authors:  Eric T Fung
Journal:  Clin Chem       Date:  2010-02       Impact factor: 8.327

4.  Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

Authors:  Deborah K Armstrong; Brian Bundy; Lari Wenzel; Helen Q Huang; Rebecca Baergen; Shashikant Lele; Larry J Copeland; Joan L Walker; Robert A Burger
Journal:  N Engl J Med       Date:  2006-01-05       Impact factor: 91.245

5.  Development of a multimarker assay for early detection of ovarian cancer.

Authors:  Zoya Yurkovetsky; Steven Skates; Aleksey Lomakin; Brian Nolen; Trenton Pulsipher; Francesmary Modugno; Jeffrey Marks; Andrew Godwin; Elieser Gorelik; Ian Jacobs; Usha Menon; Karen Lu; Donna Badgwell; Robert C Bast; Anna E Lokshin
Journal:  J Clin Oncol       Date:  2010-04-05       Impact factor: 44.544

6.  Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial.

Authors:  Saundra S Buys; Edward Partridge; Mark H Greene; Philip C Prorok; Douglas Reding; Thomas L Riley; Patricia Hartge; Richard M Fagerstrom; Lawrence R Ragard; David Chia; Grant Izmirlian; Mona Fouad; Christine C Johnson; John K Gohagan
Journal:  Am J Obstet Gynecol       Date:  2005-11       Impact factor: 8.661

7.  Development of an ovarian cancer symptom index: possibilities for earlier detection.

Authors:  Barbara A Goff; Lynn S Mandel; Charles W Drescher; Nicole Urban; Shirley Gough; Kristi M Schurman; Joshua Patras; Barry S Mahony; M Robyn Andersen
Journal:  Cancer       Date:  2007-01-15       Impact factor: 6.860

8.  Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study.

Authors:  Jeffrey Bell; Mark F Brady; Robert C Young; Janice Lage; Joan L Walker; Katherine Y Look; G Scott Rose; Nick M Spirtos
Journal:  Gynecol Oncol       Date:  2006-07-24       Impact factor: 5.482

9.  Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).

Authors:  Usha Menon; Aleksandra Gentry-Maharaj; Rachel Hallett; Andy Ryan; Matthew Burnell; Aarti Sharma; Sara Lewis; Susan Davies; Susan Philpott; Alberto Lopes; Keith Godfrey; David Oram; Jonathan Herod; Karin Williamson; Mourad W Seif; Ian Scott; Tim Mould; Robert Woolas; John Murdoch; Stephen Dobbs; Nazar N Amso; Simon Leeson; Derek Cruickshank; Alistair McGuire; Stuart Campbell; Lesley Fallowfield; Naveena Singh; Anne Dawnay; Steven J Skates; Mahesh Parmar; Ian Jacobs
Journal:  Lancet Oncol       Date:  2009-03-11       Impact factor: 41.316

10.  Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer.

Authors:  M Robyn Andersen; Barbara A Goff; Kimberly A Lowe; Nathalie Scholler; Lindsay Bergan; Charles W Drescher; Pamela Paley; Nicole Urban
Journal:  Gynecol Oncol       Date:  2009-11-28       Impact factor: 5.482
  10 in total
  3 in total

1.  Correlation Between E-cadherin Immunoexpression and Efficacy of First Line Platinum-Based Chemotherapy in Advanced High Grade Serous Ovarian Cancer.

Authors:  Branka Petrić Miše; Vesna Dobrić Telesmanić; Snježana Tomić; Dinka Šundov; Vesna Čapkun; Eduard Vrdoljak
Journal:  Pathol Oncol Res       Date:  2014-08-11       Impact factor: 3.201

2.  Cytochrome 4Z1 Expression Connotes Unfavorable Prognosis in Ovarian Cancers.

Authors:  Yousef M Al-Saraireh; Fatemah O F O Alshammari; Anas O Satari; Yanal S Al-Mahdy; Ghadeer H Almuhaisen; Omar H Abu-Azzam; Ala N Uwais; Seham M Abufraijeh; Ahlam M Al-Kharabsheh; Sa'ed M Al-Dalain; Aiman Al-Qtaitat; Fatima Al-Tarawneh; Jehad M Al Shuneigat; Sameeh A Al-Sarayreh
Journal:  Medicina (Kaunas)       Date:  2022-09-13       Impact factor: 2.948

3.  Measurement of phospholipids may improve diagnostic accuracy in ovarian cancer.

Authors:  Lian Shan; Y Ann Chen; Lorelei Davis; Gang Han; Weiwei Zhu; Ashley D Molina; Hector Arango; James P LaPolla; Mitchell S Hoffman; Thomas Sellers; Tyler Kirby; Santo V Nicosia; Rebecca Sutphen
Journal:  PLoS One       Date:  2012-10-17       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.